Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synagis' Special Status Under Health Care Reform

This article was originally published in The Pink Sheet Daily

Executive Summary

The new Medicaid rebate rules don't bite as deeply for drugs approved exclusively for pediatric use. It turns out that AstraZeneca/MedImmune's Synagis is the only therapy to qualify.

You may also be interested in...



Taking Lumps From Health Care Reform

Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA commissioner Janet Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

Topics

UsernamePublicRestriction

Register

PS071082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel